Johnson & Johnson Q3 sales rise on MedTech growth, lifts 2026 outlook
(This story was generated using AI and automation, please see disclaimer ) Overview US healthcare conglomerate's Q3 sales rose 5.9%, slightly beating analyst expectations Adjusted EPS for Q3 was $2.59, beating analyst expectations Company raised 2026 sales and adjusted EPS guidance Outlook Johnson & Johnson raises 2026